



FORMULATION AND EVALUATION OF PH INDEPENDENT FORMULATION OF FELODIPINE

B. Ravindra Babu¹, Chandra sekhar², V.Swapna³

^{1,2,3}Department of Pharmaceutics, Pulla Reddy Institute of Pharmacy, Dommadugu(v), Sangareddy(dist.) Telangana, India.

*Corresponding author Email: baggi.ravi39@gmail.com

ARTICLE INFO

Key words:

Felodipine, SLS, Wet granulation, Evaluation

Access this article online
Website:
<https://www.jgtps.com>
Quick Response Code:



ABSTRACT

All active pharmaceutical ingredients are having good therapeutic activity and show poor oral bioavailability, because of poor solubility. The present study is to investigate to improve the solubility of Felodipine using different carriers and different methods of preparation of techniques to identify that which carrier and suitable method of preparation. All formulations are evaluated for hardness, friability, drug content uniformity, and in vitro dissolution studies. Among all the formulations three formulations show good drug release and the formulation with direct compression method shows good drug release compared to other formulations among all the formulations (Eudragit RLPO, Eudragit RSPO and Ethyl cellulose N50) with direct compression is considered as ideal formulation from the study.

INTRODUCTION

Felodipine is used to treat high blood pressure (hypertension). Lowering high blood pressure helps prevent strokes, heart attacks, and kidney problems. Felodipine is known as a calcium channel blocker. By blocking calcium, this medication relaxes and widens blood vessels so blood can flow more easily.

METHODOLOGY:

Analytical Method Development:

Preparation of 6.8 Sodium phosphate buffer contains 2% SLS: 12gms of sodium di hydrogen ortho phosphate was taken in a 100ml volumetric flask and dissolved with distilled water and made up to 100 ml. Add 2 gms of SLS to the above solution (100ml 6.8 sodium phosphate buffer) and dissolved.

Determination of λ_{max} of Felodipine 6.8 Sodium phosphate buffer contains 2% SLS:

Procedure:

Working standard: 50mg of Felodipine was weighed and dissolved in 50ml **6.8 Sodium phosphate buffer contains 2% SLS** and then made up to a volume of 50ml with **6.8 Sodium phosphate buffer contains 2% SLS** it gives 1000 μ g/ml ppm concentrated stock solution.

Dilution 1: From the working standard solution 10ml was diluted to 100ml with **6.8 Sodium phosphate buffer contains 2% SLS** it will give 10 μ g/ml concentrated solution.

Dilution 2: From the working standard solution 10ml was diluted to 100ml with **6.8 Sodium phosphate buffer contains 2% SLS** it will give 10 μ g/ml concentrated solution.

This solution was scanned at a range of 200-400nm wavelength light corresponding scan spectrum curve was noted. The corresponding wavelength having highest absorbance is noted as λ_{max} .

Formulation of Felodipine ER tablets by Wet granulation method

Processing steps involved in Wet granulation method:

The Felodipine ER tablets were prepared by following the General Methodology as given below:

1. All ingredients (Felodipine+ Avicel PH 102 + polymer) were weighed accurately and co-sifted by passing through #22 sieve, blended in a Poly Bag for 5 min.
2. Above blend were granulated with Iso propyl alcohol.
3. The above granules were lubricated with # 40 Sieve passed Magnesium stearate, Aerosil and Cros carmellose sodium.
4. The final blend was then compressed into tablets using 16 station tablet compression machine with an average hardness of 4.0kg/cm², by using 8mm to 12mm dies
5. Evaluation Of Tablets
6. The formulated tablets were evaluated for the following Pre, post compression quality control studies & In vitro Buoyancy studies and dissolution studies

A) Pre Compression studies:

Angle of Repose: It is defined as the maximum angle possible between the surface of a pile of powder and the horizontal plane.

Angle of Repose of granules was determined by the funnel method. Accurately weighed powder blend was taken in the funnel. Height of the funnel was adjusted in such a way the tip of the funnel just touched the apex of the powder blend. Powder blend was allowed to flow through the funnel freely on to the surface. Diameter of the powder cone was measured and angle of repose was calculated using the following equation.

$$\theta = \tan^{-1} (h/r)$$

Where

θ = angle of repose

h = height in cms

r = radius in cms

Assay Procedure

Weigh and finely powder not less than 20 tablets. Transfer an accurately weighed portion of the powder equivalent to about 10mg Of model drug a 10 ml volumetric flask. Add approximately 6ml of 6.8 Sodium phosphate buffer contains 2% SLS and shake and sonicate for 10 min to complete the extraction. Dilute the methanol to volume and mix. Pipette 1ml aliquot into a 10ml volumetric flask, dilute with mobile phase to volume, mix and filter. From it withdraw take 1ml aliquot and make up to mark with buffer.

Calculate the quantity in mg of model drug Hydrochloride in the portion taken by the formula

$$\text{assay} = \frac{T}{\text{test}} \times \frac{\text{absorbance/standard}}{\text{absorbance*standard concentration/sample concentration*purity of drug/100*100}}$$

Parameter	Details
Dissolution apparatus	USP -Type II (paddle)
Medium	0.1N HCl.
Volume	900 ml
Speed	50rpm
Temperature	37± 0.5 °C
Sample volume withdrawn	5ml
Time points	1,2,4,6,8,10,12, 16 and 20hr
Analytical method	Ultraviolet Visible Spectroscopy
λ_{max}	282 nm

In vitro Dissolution Study:

900 ml of 6.8 Sodium phosphate buffer contains 2% SLS was placed in the vessel and the USP-II apparatus (Paddle method) was assembled. The medium was allowed to equilibrate to temperature of 37°C±0.5°C. A tablet was placed in the vessel and was covered; the apparatus was operated up to 12 hrs at 50 rpm. At definite time intervals, 5 ml of dissolution medium was withdrawn; filtered and again replaced with 5 ml of fresh medium to maintain sink conditions. Suitable dilutions were done with dissolution medium and were analyzed spectrophotometrically at $\lambda_{\text{max}} = 282$ nm using a UV-spectrophotometer (Lab India)

Table 1: Flow Properties and Corresponding Angles of Repose

Flow Property	Angle of Repose (degrees)
Parameter	Details
Dissolution apparatus	USP -Type II (paddle)
Medium	0.1N HCl.
Volume	900 ml
Speed	50rpm
Temperature	37± 0.5 °C
Sample volume withdrawn	5ml
Time points	1,2,4,6,8,10,12, 16 and 20hr
Analytical method	Ultraviolet Visible Spectroscopy
λ_{max}	282 nm
Excellent	25–30
Good	31–35
Fair—aid not needed	36–40
Passable—may hang up	41–45
Poor—must agitate, vibrate	46–55
Very poor	56–65
Very, very poor	>66

Table 2: Standard calibration values of felodipine

Evaluation of Tablets:

Table 3: Pre Compression studies

Formulation Code	Bulk density (Kg/cm ³)	Tapped density (Kg/cm ³)	Cars index	Hausners ratio	Angle of repose (°)
F1	0.43	0.52	17.3	1.41	12.62
F2	0.40	0.46	13.0	1.5	12.29
F3	0.50	0.58	13	1.16	11.58
F4	0.44	0.51	13.7	1.25	9.29
F5	0.39	0.47	17.0	1.56	18.23
F6	0.42	0.52	19.2	1.45	13.24
F7	0.36	0.39	7.6	1.0	11.03
F8	0.41	0.50	18	1.5	17.4
F9	0.39	0.48	18	1.23	11.96
F10	0.41	0.51	19.6	1.53	12.26
F11	0.44	0.52	15.3	1.40	13.62
F12	0.41	0.45	8.8	1.0	11.85

Inference:

- The Felodipine ER tablets were evaluated for their flow properties; the results for the blends of compression tablets were shown in Table:10
- The bulk density and the tapped density for all formulations were found to be almost similar.

Standard plot of **Felodipine** plotted by taking absorbance on Y – axis and concentration (µg/ml) on X – axis.




Fig. 1: standard calibration curve of felodipine

Inference: The standard calibration curve of **Felodipine** in **6.8 sodium phosphate buffer** showed good correlation with regression value of 0.9993

- The Carr's index and Hausner's ratio were found to be in the range of ≤ 18 and 1.0 to 1.56 respectively, indicating good flow and compressibility of the blends.
- The angle of repose for all the formulations was found to be in the range of 11.03-18.23° which indicating passable flow (i.e. incorporation of glidant will enhance its flow).

Table 4: Post compression studies

Formulation Code	% weight variation	Thickness	% Friability	%Drug Content	Hardness (Kg/cm ²)
F1	pass	3.16±0.11	0.22	102.0 ±1.1	4.68 ±0.17
F2	pass	3.53±0.15	0.15	101.3 ±1.5	5.13 ±0.15
F3	pass	4.06±0.057	0.12	99.8±1.3	5.58 ±0.13
F4	pass	5.1±0.1	0.43	101.7 ±0.8	5.98 ±0.04
F5	pass	3.03±0.05	0.32	100.6±1.2	4.63 ±0.05
F6	pass	3.83±0.15	0.14	98.9 ±2.1	5.2 ±0.02
F7	pass	4.93±0.05	0.20	99.2± 1.7	5.7 ±0.10
F8	pass	5.26±0.1	0.33	99.5± 1.4	5.93 ±0.05
F9	pass	3.02±0.2	0.18	99.2±1.3	4.39 ±0.02
F10	pass	3.48±0.14	0.21	100.3 ±1.4	4.86 ±0.03
F11	pass	4.91±0.18	0.32	101.2± 1.6	5.72 ±0.12
F12	pass	5.14±0.12	0.16	100.3 ±1.8	5.89 ±0.13

Post compression studies of Felodipine ER tablets

*Test for Friability was performed on single batch of 20 tablets

Inference

- The variation in weight was within the limit
- The thickness of tablets was found to be between 3.03 -5.26 mm.
- The hardness for different formulations was found to be

between 4.39 to 5.98 kg/cm², indicating satisfactory mechanical strength

- The friability was < 1.0% W/W for all the formulations, which is an indication of good mechanical resistance of the tablet.
- The drug content was found to be within limits 98 to 102 %.

INVITRO DISSOLUTION STUDIES OF FELODIPINE ER TABLETS

Table 5: Dissolution profile:

Parameter	Details
Dissolution apparatus	USP -Type II (paddle)
Medium	6.8 sodium phosphate buffer
Volume	900 ml
Speed	50rpm
Temperature	37± 0.5 °C
Sample volume withdrawn	5ml
Time points	1,2,4,6,8,10,12, 16 and 20hr
Analytical method	Ultraviolet Visible Spectroscopy
λ_{max}	282 nm

STABILITY STUDIES OF PHYSICAL AND CHEMICAL PARAMETERS:

Selected formulation F3 was stored at 40°C ± 2°C / 75% ± 5% RH and 25°C ± 2°C / 60% ± 5% RH or a period of 3 months. Samples were analyzed after storage for 1,2and 3 months and evaluated.

SUMMARY AND CONCLUSION

The approach of the present study was to make a comparative evaluation among these polymers (Eudragit RLPO, Eudragit RSPO and Ethyl cellulose N50) and to assess the effect of physico-chemical nature of the active ingredients on the drug release profile.

The angle of repose, compressibility index and sieve analysis results shown that the formulation is suitable for wet granulation.

This study have been showed that Felodipine could be used in extended release drug delivery system by formulating it has extended drug delivery system, provides extend duration of action in therapeutic range without reaching toxic levels as in the case of conventional dosage forms. These dosage forms have the ability to reduce the dosing frequency and increasing.

The technique employed in the preparation of matrix system i.e. wet granulation, is highly practical and economical from the industry point of view.

By the results we can confirm that order of drug release first order and the mechanism of drug release from sustained release matrix tablets is Higuchi model.

Success of the *In vitro* drug release studies recommends the product for further *In vivo* studies, it may improve patient compliance.

REFERENCES

1. Yie.W.Chien, "Novel Drug Delivery System, 2nd edn, revised and expanded" pg 182.
2. Robinson JR, and LeeVHI(eds)(22Edition),New York Controlled Drug Delivary Fundamentals and Applications,"1987.Pg.09.
3. D.M.Brahmankar and Sunil B.Jaiswal,Biopharmaceutics and Pharmacokinetics A Treatise",Pg.335-350.
4. Robert E. Nortari, "Biopharmaceutics and pharmacokinetics An Introduction" 4th edn revised and expanded,pg no.208.
5. S.P Vyas,Roop K.Khar, Controlled Drug Delivary Concepts and Advances"Pg.155-158.
6. Milo Gibaldi and Donald Perzier vol.15, "Pharmacokinetics" 2nd edn,"revised and expanded Pg.185.
7. Lisa Brannan-Peppas,Polymers in Controlled Drug Delivary"nov.1997.
8. Uttam Mandal, Veeran Gowda, Animesh Ghosh, Senthamil Selvan, Sam Solomon And Tapan Kumar Pal, Bioequivalence Study Centre, Department of Pharmaceutical Technology, Jadavpur University.
9. Syed Nisar Hussain Shah, Sajid Asghar, Muhammad Akram Choudhry, Muhammad Sajid Hamid Akash, "Formulation and evaluation of natural gum-based sustained release matrix tablets of flurbiprofen using response surface methodology" Drug Development and Industrial Pharmacy 2009, 35, (12), Pg 1470-1478.
10. Vinayak Dhopeswarkar, Janet C. O'Keeffe, Joel L. Zatz, Robert Deete and And MichaelHorton. Development of An Oral Sustained-Release Antibiotic Matrix Tablet Using In-Vitro/In-Vivo Correlations, Drug Development and Industrial Pharmacy, 1994, 20, (11), Pg 1851-1867.